Masimo (NASDAQ:MASI) Updates Q3 Earnings Guidance

Masimo (NASDAQ:MASI) updated its third quarter earnings guidance on Wednesday. The company provided earnings per share guidance of $0.81-0.86 for the period, compared to the consensus earnings per share estimate of $0.84. The company issued revenue guidance of $495-515 million, compared to the consensus revenue estimate of $502.48 million. Masimo also updated its Q3 2024 guidance to 0.810-0.860 EPS.

Analysts Set New Price Targets

A number of brokerages recently issued reports on MASI. Piper Sandler lifted their price objective on shares of Masimo from $160.00 to $165.00 and gave the company an overweight rating in a research note on Wednesday, August 7th. Needham & Company LLC reiterated a hold rating on shares of Masimo in a research note on Friday, September 20th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average target price of $144.67.

Masimo Price Performance

MASI stock opened at $133.77 on Thursday. The stock has a market cap of $7.11 billion, a price-to-earnings ratio of 91.00 and a beta of 0.98. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.09 and a quick ratio of 1.15. The company has a 50 day simple moving average of $116.15 and a 200 day simple moving average of $124.92. Masimo has a 1 year low of $75.22 and a 1 year high of $153.93.

Masimo (NASDAQ:MASI) last announced its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.09. Masimo had a net margin of 3.94% and a return on equity of 14.07%. The company had revenue of $496.30 million during the quarter, compared to the consensus estimate of $493.92 million. During the same period in the prior year, the business earned $0.62 earnings per share. The company’s revenue for the quarter was up 9.0% compared to the same quarter last year. Research analysts anticipate that Masimo will post 3.87 EPS for the current fiscal year.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.